Expression of MHC II Genes

  • G. Drozina
  • J. Kohoutek
  • N. Jabrane-Ferrat
  • B. M. Peterlin
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 290)


Innate and adaptive immunity are connected via antigen processing and presentation (APP), which results in the presentation of antigenic peptides to T cells in the complex with the major histocompatibility (MHC) determinants. MHC class II (MHC II) determinants present antigens to CD4+ T cells, which are the main regulators of the immune response. Their genes are transcribed from compact promoters that form first the MHC II enhanceosome, which contains DNA-bound activators and then the MHC II transcriptosome with the addition of the class II transactivator (CIITA). CIITA is the master regulator of MHC II transcription. It is expressed constitutively in dendritic cells (DC) and mature B cells and is inducible in most other cell types. Three isoforms of CIITA exist, depending on cell type and inducing signals. CIITA is regulated at the levels of transcription and post-translational modifications, which are still not very clear. Inappropriate immune responses are found in several diseases, including cancer and autoimmunity. Since CIITA regulates the expression of MHC II genes, it is involved directly in the regulation of the immune response. The knowledge of CIITA will facilitate the manipulation of the immune response and might contribute to the treatment of these diseases.


Human Leukocyte Antigen Locus Control Region Bare Lymphocyte Syndrome Proximal Promoter Sequence Transactivator CIITA 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Anonymous (1999) Complete sequence and gene map of a human major histocompatibility complex. The MHC sequencing consortium [comment]. Nature 401:921–923CrossRefGoogle Scholar
  2. Bachmann MF, Kopf M (2002) Balancing protective immunity and immunopathology. Curr Opin Immunol 14:413–419PubMedCrossRefGoogle Scholar
  3. Beresford GW, Boss JM (2001) CIITA coordinates multiple histone acetylation modifications at the HLA-DRA promoter. Nat Immunol 2:652–657PubMedCrossRefGoogle Scholar
  4. Calandra T, Froidevaux C, Martin C, Roger T (2003) Macrophage migration inhibitory factor and host innate immune defenses against bacterial sepsis. J Infect Dis 187[Suppl 2]:S385–S390PubMedCrossRefGoogle Scholar
  5. Cella M, Engering A, Pinet V, Pieters J, Lanzavecchia A (1997) Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature 388:782–787PubMedCrossRefGoogle Scholar
  6. Chen X, Laur O, Kambayashi T, Li S, Bray RA, Weber DA, Karlsson L, Jensen PE (2002) Regulated expression of human histocompatibility leukocyte antigen (HLA)-DO during antigen-dependent and antigen-independent phases of B cell development. J Exp Med 195:1053–1062PubMedCrossRefGoogle Scholar
  7. Cressman DE, Chin KC, Taxman DJ, Ting JP (1999) A defect in the nuclear translocation of CIITA causes a form of type II bare lymphocyte syndrome. Immunity 10:163–171PubMedCrossRefGoogle Scholar
  8. Cresswell P, Lanzavecchia A (2001) Antigen processing and recognition. Curr Opin Immunol 13:11–12PubMedCrossRefGoogle Scholar
  9. Cressman DE, O'Connor WJ, Greer SF, Zhu XS, Ting JP (2001) Mechanisms of nuclear import and export that control the subcellular localization of class II transactivator. J Immunol 167:3626–3634PubMedGoogle Scholar
  10. Durand B, Sperisen P, Emery P, Barras E, Zufferey M, Mach B, Reith W (1997) RFXAP, a novel subunit of the RFXDNA binding complex is mutated in MHC class II deficiency. EMBO J 16:1045–1055PubMedCrossRefGoogle Scholar
  11. Fontes JD, Jabrane-Ferrat N, Toth CR, Peterlin BM (1996) Binding and cooperative interactions between two B cell-specific transcriptional coactivators. J Exp Med 183:2517–2521PubMedCrossRefGoogle Scholar
  12. Fontes JD, Jiang B, Peterlin BM (1997) The class II transactivator CIITA interacts with the TBP-associated factor TAFII32. Nucleic Acids Res 25:2522–2528PubMedCrossRefGoogle Scholar
  13. Fontes JD, Kanazawa S, Jean D, Peterlin BM (1999) Interactions between the class II transactivator and CREB binding protein increase transcription of major histocompatibility complex class II genes. Mol Cell Biol 19:941–947PubMedGoogle Scholar
  14. Fruci D, Lauvau G, Saveanu L, Amicosante M, Butler RH, Polack A, Ginhoux F, Lemonnier F, Firat H, van Endert PM (2003) Quantifying recruitment of cytosolic peptides for HLA class I presentation: impact of TAP transport. J Immunol 170:2977–2984PubMedGoogle Scholar
  15. Greer SF, Zika E, Conti B, Zhu XS, Ting JP (2003) Enhancement of CIITA transcriptional function by ubiquitin. Nat Immunol 4:1074–1082PubMedCrossRefGoogle Scholar
  16. Hake SB, Masternak K, Kammerbauer C, Janzen C, Reith W, Steimle V (2000) CIITA leucine-rich repeats control nuclear localization, in vivo recruitment to the major histocompatibility complex (MHC) class II enhanceosome MHC class II gene transactivation. Mol Cell Biol 20:7716–7725PubMedCrossRefGoogle Scholar
  17. Harton JA, Cressman DE, Chin KC, Der CJ, Ting JP (1999) GTP binding by class II transactivator: role in nuclear import [comment]. Science 285:1402–1405PubMedCrossRefGoogle Scholar
  18. Harton JA, Zika E, Ting JP (2001) The histone acetyltransferase domains of CREB-binding protein (CBP) and p300/CBP-associated factor are not necessary for cooperativity with the class II transactivator. J Biol Chem 276:38715–38720PubMedCrossRefGoogle Scholar
  19. Harton JA, O'Connor W Jr, Conti BJ, Linhoff MW, Ting JP (2002) Leucine-rich repeats of the class II transactivator control its rate of nuclear accumulation. Hum Immunol 63:588–601PubMedCrossRefGoogle Scholar
  20. Holtz R, Choi JC, Petroff MG, Piskurich JF, Murphy SP (2003) Class II transactivator (CIITA) promoter methylation does not correlate with silencing of CIITA transcription in trophoblasts. Biol Reprod 69:915–924PubMedCrossRefGoogle Scholar
  21. Jabrane-Ferrat N, Fontes JD, Boss JM, Peterlin BM (1996) Complex architecture of major histocompatibility complex class II promoters: reiterated motifs and conserved protein-protein interactions. Mol Cell Biol 16:4683–4690PubMedGoogle Scholar
  22. Jabrane-Ferrat N, Nekrep N, Tosi G, Esserman LJ, Peterlin BM (2002) Major histocompatibility complex class II transcriptional platform: assembly of nuclear factor Y and regulatory factor X (RFX) on DNA requires RFX5 dimers. Mol Cell Biol 22:5616–5625PubMedCrossRefGoogle Scholar
  23. Janeway CA Jr (2001) How the immune system works to protect the host from infection: a personal view. Proc Natl Acad Sci USA 98:7461–7468PubMedCrossRefGoogle Scholar
  24. Kanazawa S, Okamoto T, Peterlin BM (2000) Tat competes with CIITA for the binding to P-TEFb and blocks the expression of MHC class II genes in HIV infection. Immunity 12:61–70PubMedCrossRefGoogle Scholar
  25. Kelly JM, Takeda K, Darcy PK, Yagita H, Smyth MJ (2002) A role for IFN-gamma in primary and secondary immunity generated by NK cell-sensitive tumor-expressing CD80 in vivo. J Immunol 168:4472–4479PubMedGoogle Scholar
  26. Kretsovali A, Spilianakis C, Dimakopoulos A, Makatounakis T, Papamatheakis J (2001) Self-association of class II transactivator correlates with its intracellular localization and transactivation. J Biol Chem 276:32191–32197PubMedCrossRefGoogle Scholar
  27. Kudo N, Wolff B, Sekimoto T, Schreiner EP, Yoneda Y, Yanagida M, Horinouchi S, Yoshida M (1998) Leptomycin B inhibition of signal-mediated nuclear export by direct binding to CRM1. Exp Cell Res 242:540–547PubMedCrossRefGoogle Scholar
  28. Landmann S, Muhlethaler-Mottet A, Bernasconi L, Suter T, Waldburger JM, Masternak K, Arrighi JF, Hauser C, Fontana A, Reith W (2001) Maturation of dendritic cells is accompanied by rapid transcriptional silencing of class II transactivator (CIITA) expression. J Exp Med 194:379–391PubMedCrossRefGoogle Scholar
  29. Li G, Harton JA, Zhu X, Ting JP (2001) Downregulation of CIITA function by protein kinase a (PKA)-mediated phosphorylation: mechanism of prostaglandin E, cyclic AMP, PKA inhibition of class II major histocompatibility complex expression in monocytic lines. Mol Cell Biol 21:4626–4635PubMedCrossRefGoogle Scholar
  30. Linhoff MW, Harton JA, Cressman DE, Martin BK, Ting JP (2001) Two distinct domains within CIITA mediate self-association: involvement of the GTP-binding and leucine-rich repeat domains. Mol Cell Biol 21:3001–3011PubMedCrossRefGoogle Scholar
  31. Mahanta SK, Scholl T, Yang FC, Strominger JL (1997) Transactivation by CIITA, the type II bare lymphocyte syndrome-associated factor, requires participation of multiple regions of the TATA box binding protein. Proc Natl Acad Sci USA 94:6324–6329PubMedCrossRefGoogle Scholar
  32. Maity SN, de Crombrugghe B (1998) Role of the CCAAT-binding protein CBF/NF-Y in transcription. Trends Biochem Sci 23:174–178PubMedCrossRefGoogle Scholar
  33. Mantovani R (1999) The molecular biology of the CCAAT-binding factor NF-Y. Gene 239:15–27PubMedCrossRefGoogle Scholar
  34. Masternak K, Barras E, Zufferey M, Conrad B, Corthals G, Aebersold R, Sanchez JC, Hochstrasser DF, Mach B, Reith W (1998) A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients. Nat Genet 20:273–277PubMedCrossRefGoogle Scholar
  35. Masternak K, Peyraud N, Krawczyk M, Barras E, Reith W (2003) Chromatin remodeling and extragenic transcription at the MHC class II locus control region. Nat Immunol 4:132–137PubMedCrossRefGoogle Scholar
  36. Matthias P (1998) Lymphoid-specific transcription mediated by the conserved octamer site: who is doing what? Semin Immunol 10:155–163PubMedCrossRefGoogle Scholar
  37. Matuoka K, Yu Chen K (1999) Nuclear factor Y (NF-Y) and cellular senescence. Exp Cell Res 253:365–371PubMedCrossRefGoogle Scholar
  38. Moreno CS, Emery P, West JE, Durand B, Reith W, Mach B, Boss JM (1995) Purified X2 binding protein (X2BP) cooperatively binds the class II MHCX box region in the presence of purified RFX, the X box factor deficient in the bare lymphocyte syndrome. J Immunol 155:4313–4321PubMedGoogle Scholar
  39. Moreno CS, Rogers EM, Brown JA, Boss JM (1997) Regulatory factor X, a bare lymphocyte syndrome transcription factor, is a multimeric phosphoprotein complex. J Immunol 158:5841–5848PubMedGoogle Scholar
  40. Morris AC, Spangler WE, Boss JM (2000) Methylation of class II trans-activator promoter IV: a novel mechanism of MHC class II gene control. J Immunol 164:4143–4149PubMedGoogle Scholar
  41. Morris AC, Beresford GW, Mooney MR, Boss JM (2002) Kinetics of a gamma interferon response: expression and assembly of CIITA promoter IV and inhibition by methylation. Mol Cell Biol 22:4781–4791PubMedCrossRefGoogle Scholar
  42. Mudhasani R, Fontes JD (2002) The class II transactivator requires brahma-related gene 1 to activate transcription of major histocompatibility complex class II genes. Mol Cell Biol 22:5019–5026PubMedCrossRefGoogle Scholar
  43. Muhlethaler-Mottet A, Otten LA, Steimle V, Mach B (1997) Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA. EMBO J 16:2851–2860PubMedCrossRefGoogle Scholar
  44. Muhlethaler-Mottet A, Di Berardino W, Otten LA, Mach B (1998) Activation of the MHC class II transactivator CIITA by interferon-gamma requires cooperative interaction between Stat1 and USF-1. Immunity 8:157–166PubMedCrossRefGoogle Scholar
  45. Nagarajan UM, Louis-Plence P, DeSandro A, Nilsen R, Bushey A, Boss JM (1999) RFX-B is the gene responsible for the most common cause of the bare lymphocyte syndrome, an MHC class II immunodeficiency. Immunity 10:153–162PubMedCrossRefGoogle Scholar
  46. Nekrep N, Jabrane-Ferrat N, Wolf HM, Eibl MM, Geyer M, Peterlin BM (2002) Mutation in a winged-helix DNA-binding motif causes atypical bare lymphocyte syndrome. Nat Immunol 3:1075–1081PubMedCrossRefGoogle Scholar
  47. Nekrep N, Fontes JD, Geyer M, Peterlin BM (2003) When the lymphocyte loses its clothes. Immunity 18:453–457PubMedCrossRefGoogle Scholar
  48. Nickerson K, Sisk TJ, Inohara N, Yee CS, Kennell J, Cho MC, Yannie PJ 2nd, Nunez G, Chang CH (2001) Dendritic cell-specific MHC class II transactivator contains a caspase recruitment domain that confers potent transactivation activity. J Biol Chem 276:19089–19093PubMedCrossRefGoogle Scholar
  49. Paraskeva E, Izaurralde E, Bischoff FR, Huber J, Kutay U, Hartmann E, Luhrmann R, Gorlich D (1999) CRM1-mediated recycling of snurportin 1 to the cytoplasm. J Cell Biol 145:255–264PubMedCrossRefGoogle Scholar
  50. Pierre P, Turley SJ, Gatti E, Hull M, Meltzer J, Mirza A, Inaba K, Steinman RM, Mellman I (1997) Developmental regulation of MHC class II transport in mouse dendritic cells. Nature 388:787–792PubMedCrossRefGoogle Scholar
  51. Piskurich JF, Lin KI, Lin Y, Wang Y, Ting JP, Calame K (2000) BLIMP-I mediates extinction of major histocompatibility class II transactivator expression in plasma cells. Nat Immunol 1:526–532PubMedCrossRefGoogle Scholar
  52. Raval A, Howcroft TK, Weissman JD, Kirshner S, Zhu XS, Yokoyama K, Ting J, Singer DS (2001) Transcriptional coactivator CIITA, is an acetyltransferase that bypasses a promoter requirement for TAF(II)250. Mol Cell 7:105–115PubMedCrossRefGoogle Scholar
  53. Raval A, Weissman JD, Howcroft TK, Singer DS (2003) The GTP-binding domain of class II transactivator regulates its nuclear export. J Immunol 170:922–930PubMedGoogle Scholar
  54. Reith W, Mach B (2001) The bare lymphocyte syndrome and the regulation of MHC expression. Annu Rev Immunol 19:331–373PubMedCrossRefGoogle Scholar
  55. Riley JL, Boss JM (1993) Class II MHC transcriptional mutants are defective in higher order complex formation. J Immunol 151:6942–6953PubMedGoogle Scholar
  56. Saveanu L, Fruci D, van Endert P (2002) Beyond the proteasome: trimming, degradation and generation of MHC class I ligands by auxiliary proteases. Mol Immunol 39:203–215PubMedCrossRefGoogle Scholar
  57. Schnappauf F, Hake SB, Camacho Carvajal MM, Bontron S, Lisowska-Grospierre B, Steimle V (2003) N-terminal destruction signals lead to rapid degradation of the major histocompatibility complex class II transactivator CIITA. Eur J Immunol 33:2337–2347PubMedCrossRefGoogle Scholar
  58. Setterblad N, Peterlin BM, Andersson G (1997) Role of the X2 box in activated transcription from the DRA promoter in B cells. Immunogenetics 46:318–325PubMedCrossRefGoogle Scholar
  59. Sisk TJ, Nickerson K, Kwok RP, Chang CH (2003) Phosphorylation of class II transactivator regulates its interaction ability and transactivation function. Int Immunol 15:1195–1205PubMedCrossRefGoogle Scholar
  60. Smyth MJ, Godfrey DI, Trapani JA (2001) A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2:293–299PubMedCrossRefGoogle Scholar
  61. Smyth MJ, Takeda K, Hayakawa Y, Peschon JJ, van den Brink MR, Yagita H (2003) Nature's TRAIL—on a path to cancer immunotherapy. Immunity 18:1–6PubMedCrossRefGoogle Scholar
  62. Spilianakis C, Papamatheakis J, Kretsovali A (2000) Acetylation by PCAF enhances CIITA nuclear accumulation and transactivation of major histocompatibility complex class II genes. Mol Cell Biol 20:8489–8498PubMedCrossRefGoogle Scholar
  63. Steimle V, Otten LA, Zufferey M, Mach B (1993) Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell 75:135–146PubMedCrossRefGoogle Scholar
  64. Steimle V, Durand B, Barras E, Zufferey M, Hadam MR, Mach B, Reith W (1995) A novel DNA-binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte syndrome). Genes Dev 9:1021–1032PubMedGoogle Scholar
  65. Takeda K, Kaisho T, Akira S (2003) Toll-like receptors. Ann Rev Immunol 21:335–376CrossRefGoogle Scholar
  66. Ting JP, Trowsdale J (2002) Genetic control of MHC class II expression. Cell 109[Suppl]:S21–S33PubMedCrossRefGoogle Scholar
  67. Tosi G, Jabrane-Ferrat N, Peterlin BM (2002) Phosphorylation of CIITA directs its oligomerization, accumulation and increased activity on MHCII promoters. EMBO J 21:5467–5476PubMedCrossRefGoogle Scholar
  68. Towey M, Kelly AP (2002) Nuclear localisation of CIITA is controlled by a carboxy terminal leucine-rich repeat region. Mol Immunol 38:627–634PubMedCrossRefGoogle Scholar
  69. Turley SJ, Inaba K, Garrett WS, Ebersold M, Unternaehrer J, Steinman RM, Mellman I (2000) Transport of peptide-MHC class II complexes in developing dendritic cells. Science 288:522–527PubMedCrossRefGoogle Scholar
  70. Van den Elsen PJ, van der Stoep N, Vietor HE, Wilson L, van Zutphen M, Gobin SJ (2000) Lack of CIITA expression is central to the absence of antigen presentation functions of trophoblast cells and is caused by methylation of the IFN-gamma inducible promoter (PIV) of CIITA. Hum Immunol 61:850–862PubMedCrossRefGoogle Scholar
  71. Waldburger JM, Suter T, Fontana A, Acha-Orbea H, Reith W (2001) Selective abrogation of major histocompatibility complex class II expression on extrahematopoietic cells in mice lacking promoter IV of the class II transactivator gene [comment]. J Exp Med 194:393–406PubMedCrossRefGoogle Scholar
  72. Zika E, Greer SF, Zhu XS, Ting JP (2003) Histone deacetylase 1/mSin3A disrupts gamma interferon-induced CIITA function and major histocompatibility complex class II enhanceosome formation. Mol Cell Biol 23:3091–3102PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • G. Drozina
    • 1
  • J. Kohoutek
    • 1
  • N. Jabrane-Ferrat
    • 2
  • B. M. Peterlin
    • 1
  1. 1.Departments of Medicine, Microbiology and Immunology, Rosalind Russell Medical Research CenterUniversity of CaliforniaSan FranciscoUSA
  2. 2.Structural Immuno-PharmacologyInstitute of Pharmacology and Structural BiologyToulouseFrance

Personalised recommendations